Cyclacel Pharmaceuticals Inc (CYCC)
NASDAQ
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -53.982 | -65.021 | -32.685 | -45.72 | -47.672 | -48.087 | -61.063 | -125.357 |
Return on Equity (%) | -72.436 | -82.389 | -40.44 | -59.557 | -55.258 | -54.133 | -81.1 | -282.403 |
Return on Invested Capital (%) | -73.262 | -47.185 | -44.414 | -62.084 | -41.806 | -55.338 | -86.731 | -273.873 |
Operating Margin (%) | -1633.926 | N/A | -5750 | N/A | N/A | N/A | N/A | -6083.571 |
Net Profit Margin (%) | -1422.42 | N/A | -4992.667 | N/A | N/A | N/A | N/A | -5418.095 |
Book Value Per Share | 3.108 | 1.765 | 1.19 | 0.912 | 5.053 | 3.527 | 1.526 | 0.045 |
Earnings Per Share | -2.611 | -1.204 | -0.584 | -0.626 | -1.887 | -1.807 | -1.632 | -1.679 |
Cash Per Share | 3.598 | 1.939 | 1.364 | 0.058 | 4.266 | 3.46 | 1.399 | 0.249 |
Working Capital Per Share | 3.127 | 1.773 | 1.195 | 0.904 | 5.011 | 3.374 | 1.298 | -0.053 |
Operating Profit Per Share | 0.184 | N/A | 0.012 | N/A | N/A | N/A | N/A | 0.031 |
EBIT Per Share | -3 | -0.686 | -0.672 | -0.711 | -1.471 | -2.152 | -1.976 | -1.886 |
EBITDA Per Share | -3 | -0.686 | -0.672 | -0.711 | -1.471 | -2.152 | -1.976 | -1.886 |
Free Cash Flow Per Share | -2.632 | -1.205 | -0.583 | -0.627 | -1.876 | -1.808 | -1.634 | -1.681 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 4,26M | 12M | 12,5M | 12,5M | 6,25M | 9,99M | 12,54M | N/A |
Fin d'année 31 Décembre 2023 | Sept 2022 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | 12,54M | 12,54M | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | -14827.586 | N/A |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | -10158.621 | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 2,08M |
Ratio cours/bénéfice | -0,09 |
Ratio prix/ventes | 4,94 |
Ratio prix/liquidités | 0,61 |
Ratio prix/valeur comptable | 3,42 |
Rendement de dividende | - |
Actions en circulation | 6,29M |
Volume moyen (1 semaine) | 283,04k |
Volume moyen (1 mois) | 442,42k |
Variation sur 52 semaines | -90,12% |
Plus haut sur 52 semaines | 4,00 |
Plus bas sur 52 semaines | 0,32 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales